Our clinical investigations revealed a strong link between pericyte‐IL32 expression and prognosis in EGFR‐mutated NSCLC patients undergoing third‐generation TKI treatment, suggesting it may indicate their response to treatment. This evidence concerns the gene IL32 and non-small cell lung carcinoma.